Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like Merck Laying Off 50 Employees in North Carolina December 10, 2017 New York's Akari Puts CEO on Administrative Leave May 11, 2017 Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017
